Ah—where are you seeing that? The endTB page mentions under "What's next?" the phase III endTB-Q trial, but that's for pre-XDR TB, with "results [...] expected in late 2024".
"directly observed therapy, short-chouse (DOTS) coverage" looks like a somewhat confusing typo of "directly observed therapy, short-course (DOTS) coverage", unless I'm about to learn a new medical term.
Ah—where are you seeing that? The endTB page mentions under "What's next?" the phase III endTB-Q trial, but that's for pre-XDR TB, with "results [...] expected in late 2024".
Thanks! I don't use LinkedIn—is it within the bounds of propriety to tag his EA Forum account here?
"directly observed therapy, short-chouse (DOTS) coverage" looks like a somewhat confusing typo of "directly observed therapy, short-course (DOTS) coverage", unless I'm about to learn a new medical term.